* In the news *
Synthetic Biologics, Inc., a biotechnology company developing novel pathogen-specific therapies for serious infections and diseases, announced that as of October 22, 2014 the U.S. Patent and Trademark Office has issued a Notice of Allowance for a composition of matter patent application that covers the lead product in its C. difficile program, SYN-004. This is Synthetic Biologics’ first allowed patent application directly pertaining to SYN-004 in the U.S. and adds to the Company’s extensive C. difficile patent estate.
SYN-004 is Synthetic Biologics’ novel oral enzyme drug candidate designed as the first and only prophylactic treatment intended to prevent the development of C. difficile infections, by binding with and neutralizing certain intravenous (IV) beta-lactam antibiotics in the gut.
SYN-004 is intended to block the effects of antibiotics within the gastrointestinal (GI) tract, maintaining the natural balance of bacterial flora (the gut microbiome), potentially preventing the 1.1 million C. difficile infections in the U.S. each year. The U.S. patent to be issued has claims to compositions of matter and pharmaceutical compositions of beta-lactamases, including SYN-004, and carries a patent term to at least 2031. In addition to the newly allowed patent, the Company has numerous related granted and pending U.S. and international patent applications that are central to the Synthetic Biologics’ intellectual property estate.
“This new patent will strengthen the protection of Synthetic Biologics’ SYN-004 and reiterates our position as a key player in the prevention of microbiome-based diseases,” said Jeffrey Riley, Chief Executive Officer of Synthetic Biologics. “We continue to bolster the Company’s patent estate while making progress towards our goals to initiate Phase Ia and Ib C. difficile clinical trials this quarter.”
Resource: Synthetic Biologics news release.
*Please note – The C Diff Foundation does not endorse this product or any product and this posting is strictly for informational purposes only.